3-Methylthio-1-cyclopentene | 27557-68-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3-Methylthio-1-cyclopentene
• 英文别名: 3-Methylthiocyclopenten；3-Methylsulfanylcyclopentene
• CAS: 27557-68-2
• 化学式: C₆H₁₀S
• 分子量: 114.211
• InChiKey: ZWUZLNAIYKYZET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-chloro-2-methylthiocyclopentane 在 sodium methylate 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 8.0h， 生成 3-Methylthio-1-cyclopentene
  参考文献：
  名称：

  Gritsenko, E. I.; Butenko, G. G.; Plemenkov, V. V., Journal of Organic Chemistry USSR (English Translation), 1984, vol. 20, p. 673 - 678

  摘要：

  DOI：

文献信息

• METHOD FOR PRODUCING CYCLOPENTYL ALKYL ETHER COMPOUND
  申请人：ZEON CORPORATION

  公开号：US20170217862A1

  公开（公告）日：2017-08-03

  The present invention is a method for producing a cyclopentyl alkyl ether compound comprising reacting substituted or unsubstituted cyclopentene with an alcohol compound represented by a formula (2): R 1 OH in the presence of an acidic zeolite, the cyclopentyl alkyl ether compound being represented by a formula (1): R 1 —O—R 2 , wherein R 1 represents a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 8 carbon atoms, and R 2 represents a substituted or unsubstituted cyclopentyl group. The present invention provides a method that can produce a cyclopentyl alkyl ether with high reaction efficiency through a liquid-phase reaction even when the raw material feed rate (amount) is increased.

  本发明涉及一种制备环戊基烷基醚化合物的方法，包括在酸性沸石的存在下，将取代或未取代的环戊烯与式（2）表示的醇化合物（R1OH）反应，所述环戊基烷基醚化合物由式（1）表示：R1-O-R2，其中R1表示具有1到10个碳原子的取代或未取代的烷基或具有3到8个碳原子的取代或未取代的环烷基，R2表示取代或未取代的环戊基。本发明提供了一种方法，即使原料进料速率（量）增加，也可以通过液相反应高效地生产环戊基烷基醚。
• METHOD FOR PRODUCING CYCLOALKYL ALKYL ETHER COMPOUND
  申请人：ZEON CORPORATION

  公开号：US20160052848A1

  公开（公告）日：2016-02-25

  The present invention is a method for producing a cycloalkyl alkyl ether compound comprising reacting substituted or unsubstituted cyclopentene or substituted or unsubstituted cyclohexene with an alcohol compound represented by a formula (2): R 1 OH (wherein R 1 is a substituted or unsubstituted alkyl group having 1 to 10 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 8 carbon atoms) in a gaseous state in presence of an acidic ion-exchange resin to produce a cycloalkyl alkyl ether compound represented by a formula (1): R 1 —O—R 2 (wherein R 1 is the same as defined above, and R 2 is a substituted or unsubstituted cyclopentyl group or a substituted or unsubstituted cyclohexyl group), the acidic ion-exchange resin having a specific surface area of 20 to 50 m 2 /g, an average pore size of 20 to 70 nm, and a total exchange capacity of 4.8 to 6.0 eq/L-R wet resin.

  本发明是一种生产环烷基烷基醚化合物的方法，包括将取代或未取代的环戊烯或取代或未取代的环己烯与公式（2）所表示的醇化合物反应：R1OH（其中R1是具有1至10个碳原子的取代或未取代的烷基或具有3至8个碳原子的取代或未取代的环烷基），在酸性离子交换树脂的存在下，在气态下生产环烷基烷基醚化合物，该化合物的化学式为（1）：R1—O—R2（其中R1与上述定义相同，R2是取代或未取代的环戊基或取代或未取代的环己基），酸性离子交换树脂具有20至50 m2/g的比表面积，20至70 nm的平均孔径和4.8至6.0 eq/L-R湿树脂的总交换容量。
• Methods and compositions for treatment of demyelinating diseases
  申请人：Pathologica LLC

  公开号：US10085955B2

  公开（公告）日：2018-10-02

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.

  本文公开了SAMDC抑制剂、多胺类似物和多胺生物合成抑制剂的新型口服药物组合物，以及它们在治疗脱髓鞘疾病、影响神经系统的自身免疫性疾病和其他神经退行性疾病等疾病中的应用。
• Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
  申请人：Pathologica LLC

  公开号：US10292950B2

  公开（公告）日：2019-05-21

  Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase.

  本文公开了用于治疗炎症和/或疼痛等疾病的化合物、药物组合物和方法，其中包括施用治疗有效量的非类固醇、非阿片类化合物，该化合物具有胃肠道/肾脏/血小板疏松活性和较宽的安全边际，对两种形式的环氧化酶均无明显抑制作用。
• Controlled release oral pharmaceutical dosage forms comprising MGBG
  申请人：Pathologica LLC

  公开号：US10881626B2

  公开（公告）日：2021-01-05

  Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

  本文公开了包含 MGBG 的控释口服药物剂型，以及它们在改善疾病治疗、减少副作用和/或延长最大浓度时间方面的应用。